当前位置: X-MOL 学术J. Mol. Struct. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Investigation of MI-2 analogues as MALT1 inhibitors to treat of diffuse large B-Cell lymphoma through combined molecular dynamics simulation, molecular docking and QSAR techniques and design of new inhibitors
Journal of Molecular Structure ( IF 4.0 ) Pub Date : 2019-03-01 , DOI: 10.1016/j.molstruc.2018.12.022
Hossein Safarizadeh , Zahra Garkani-Nejad

Abstract Mucosa-associated lymphoid tissue lymphoma translocation protein-1 (MALT1) has emerged as a promising therapeutic target for the treatment of activated B cell–like diffuse large B-cell lymphoma (ABC-DLBCL). To develop more potent MALT1 inhibitors, a series of MI-2 analogues were investigated using combined molecular modeling techniques such as molecular dynamics (MD) simulation, molecular docking and quantitative structure-activity relationship (QSAR). 40 ns MD simulations were successfully performed on the docked complexes of reference compound (MI-2) and compound 33 (one of highly active compounds of the data set) to investigate the binding stability and specifying the active site of the MALT1 enzyme in interaction with inhibitors. A few key residues (GLY416 and GLU500) at the binding site of MALT1 enzyme were identified. Using molecular docking was understood that hydroxyl groups along with groups of dichlorophenyl, chlorobenzyl and fluorobenzyl help to create interactions between the MI-2 analogues and enzyme residues to stabilize the conformation of compounds at the binding pocket. A robust and reliable QSAR model, as evidenced by the high R2, Q2LOO and R2ext values (0.933, 0.891 and 0.970, respectively), was gained based on the MI-2 analogues to predict the quantitative chemical-biological relationship and predict the inhibitory activity of new drug compounds. Then ten new MI-2 analogues have been designed that provide better inhibitory activity with the MALT1 enzyme than the reference compounds.

中文翻译:

MI-2 类似物作为 MALT1 抑制剂治疗弥漫性大 B 细胞淋巴瘤的研究,通过结合分子动力学模拟、分子对接和 QSAR 技术以及新抑制剂的设计

摘要 黏膜相关淋巴组织淋巴瘤易位蛋白-1 (MALT1) 已成为治疗活化 B 细胞样弥漫性大 B 细胞淋巴瘤 (ABC-DLBCL) 的有前景的治疗靶点。为了开发更有效的 MALT1 抑制剂,使用分子动力学 (MD) 模拟、分子对接和定量构效关系 (QSAR) 等组合分子建模技术研究了一系列 MI-2 类似物。对参考化合物 (MI-2) 和化合物 33(数据集中的一种高活性化合物)的对接复合物成功进行了 40 ns MD 模拟,以研究结合稳定性并指定 MALT1 酶与抑制剂。鉴定了 MALT1 酶结合位点的几个关键残基(GLY416 和 GLU500)。使用分子对接可以理解,羟基以及二氯苯基、氯苄基和氟苄基有助于在 MI-2 类似物和酶残基之间产生相互作用,以稳定结合口袋处的化合物构象。基于 MI-2 类似物的高 R2、Q2LOO 和 R2ext 值(分别为 0.933、0.891 和 0.970)证明了稳健可靠的 QSAR 模型,以预测定量化学-生物学关系并预测抑制活性新的药物化合物。然后设计了十种新的 MI-2 类似物,它们对 MALT1 酶的抑制活性比参考化合物更好。氯苄基和氟苄基有助于在 MI-2 类似物和酶残基之间产生相互作用,以稳定结合口袋处的化合物构象。基于 MI-2 类似物的高 R2、Q2LOO 和 R2ext 值(分别为 0.933、0.891 和 0.970)证明了稳健可靠的 QSAR 模型,以预测定量化学-生物学关系并预测抑制活性新的药物化合物。然后设计了十种新的 MI-2 类似物,它们对 MALT1 酶的抑制活性比参考化合物更好。氯苄基和氟苄基有助于在 MI-2 类似物和酶残基之间产生相互作用,以稳定结合口袋处的化合物构象。基于 MI-2 类似物的高 R2、Q2LOO 和 R2ext 值(分别为 0.933、0.891 和 0.970)证明了稳健可靠的 QSAR 模型,以预测定量化学-生物学关系并预测抑制活性新的药物化合物。然后设计了十种新的 MI-2 类似物,它们对 MALT1 酶的抑制活性比参考化合物更好。基于MI-2类似物预测定量化学-生物学关系并预测新药化合物的抑制活性。然后设计了十种新的 MI-2 类似物,它们对 MALT1 酶的抑制活性比参考化合物更好。基于MI-2类似物预测定量化学-生物学关系并预测新药化合物的抑制活性。然后设计了十种新的 MI-2 类似物,它们对 MALT1 酶的抑制活性比参考化合物更好。
更新日期:2019-03-01
down
wechat
bug